ONWARD Medical Seeks Regulatory Approval for ARC-EX System
ONWARD Medical N.V., a frontrunner in neurotechnology, is making significant strides toward global accessibility of its innovative ARC-EX System. The company recently submitted a 510(k) application to the US Food and Drug Administration (FDA) to secure marketing clearance for home use.
CE Mark Application and Broader Reach
In addition to its FDA application, ONWARD has also filed for CE Mark certification, which will allow for the rollout of the ARC-EX System throughout the European Union and other regions recognizing CE Marking. These initiatives are crucial parts of ONWARD's strategy to enhance patient independence and improve treatment options for those with spinal cord injuries (SCI).
The Groundbreaking ARC-EX System
The ARC-EX System stands out as the first FDA-cleared technology designed to enhance hand strength and sensation post-SCI. Following a successful initial clinic launch, ONWARD is now targeting home use to facilitate greater patient access, reflecting strong demand and enthusiasm from early users.
Significant Milestones for ONWARD Medical
Dave Marver, Chief Executive Officer of ONWARD Medical, commented on these applications, expressing confidence that successfully obtaining the necessary regulatory approvals will enhance market access and make therapies more convenient for individuals with SCI. The submissions mark pivotal steps not just for the company, but potentially for thousands who seek to regain autonomy through innovative technologies.
Clinical Insights and Research
Furthermore, ONWARD Medical has achieved recognition for its rigorous clinical studies. Earlier this year, they published positive outcomes from the Pathfinder2 Study in a peer-reviewed journal, demonstrating the effectiveness of ARC-EX Therapy. This study, which involved one-year follow-ups, highlighted significant improvements in upper body strength, trunk control, and balance.
The Future of Neurotechnology
With its commitment to developing advanced therapies for movement restoration, ONWARD continues to innovate. The ongoing development of its investigational implantable system, ARC-IM, shows the company's dedication to exploring new frontiers in neurotechnology.
About ONWARD Medical
Headquartered in the Netherlands, ONWARD Medical has an operational presence in the United States and a research center in Switzerland. The company’s efforts are supported by a robust foundation of scientific research spanning over a decade, positioning ONWARD at the forefront of neurotechnology.
Stay Connected
Both Euronext listings (ticker: ONWD) and OTCQX listings (ticker: ONWRY) allow investors to engage with ONWARD's journey and growth. For up-to-date news and information about this innovative company, connecting with them through their official channels is encouraged.
Frequently Asked Questions
What is the purpose of the ARC-EX System?
The ARC-EX System is designed to improve hand sensation and strength in individuals with spinal cord injuries through advanced neurotechnology.
Where will ONWARD Medical launch the ARC-EX System?
The ARC-EX System is set for launch in both the United States, pending FDA approval, and in Europe after CE Mark certification.
What regulatory steps are ONWARD Medical taking?
ONWARD Medical has submitted a 510(k) application to the FDA and a CE Mark application for regulatory approval.
What clinical studies support the ARC-EX System's effectiveness?
The Pathfinder2 Study provided extensive clinical evidence showing significant benefits for users, including increased upper body strength and balance.
How can I stay updated on ONWARD Medical's offerings?
Engaging with ONWARD’s website and social media channels will provide ongoing updates about their technologies and future initiatives.
